JAZZ — Jazz Pharmaceuticals plc

Jazz Pharmaceuticals Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $1.2 billion, a 10% increase year-over-year, marking the highest revenue quarter in the company's history.
• Full Year 2025 Revenue: $4.3 billion, representing a 5% growth over 2024.
• Non-GAAP Adjusted Net Income: Approximately $522 million, with a non-GAAP adjusted EPS of $8.38.
• Key Revenue Contributors:
  • Xywav: $1.7 billion for the year (+12% YoY), $465 million in Q4 (+16% YoY).
  • Epidiolex: $1.1 billion for the year (+9% YoY), $287 million in Q4 (+4% YoY).
  • Modeyso: $48 million since its August launch.

2. Strategic Updates and Business Highlights

• Acquisitions and Product Launches:
  • Acquired Chimerix, leading to the launch of Modeyso.
  • Zepzelca received approval for a new indication in first-line maintenance for small cell lung cancer.
• R&D Progress:
  • Positive Phase III data for zanidatamab in HER2-positive metastatic gastric cancer, with plans for further development in breast cancer.
  • Initiated new trials, including JZP047 for absence epilepsy.
• Litigation Resolutions: Resolved major litigation issues, enhancing future operational flexibility.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $4.25 billion and $4.50 billion, indicating a growth of about 2.5% at the midpoint compared to 2025.
• Rare Oncology and Epilepsy Growth: Anticipated double-digit growth in these segments, driven by Epidiolex, Modeyso, and Ziihera.
• Rare Sleep Franchise: Expected to decline to $1.8 billion - $1.9 billion due to increased competition from generics.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures:
  • The introduction of multiple generics for high-sodium oxybate is expected to impact Xywav sales, particularly in the second half of 2026.
  • Potential payer negotiations may arise due to competitive dynamics and the introduction of new wake-promoting agents.
• Declining Metrics: Anticipated revenue decline in the rare sleep segment, particularly for Xyrem, which generated $146 million in 2025.
• Market Uncertainties: The evolving landscape in sleep medicine could affect Xywav's market position.

5. Notable Q&A Insights

• Xywav Guidance: Management indicated that while Xywav is well-positioned, the impact of generics will be more significant in the second half of 2026, with a focus on maintaining its unique value proposition.
• Modeyso Launch: Early metrics are promising, with a peak sales opportunity of over $500 million contingent on the success of the ACTION trial.
• Acquisition Strategy: Jazz is open to leveraging its balance sheet for strategic acquisitions, particularly in areas that align with its focus on rare diseases.
• Epidiolex Growth: Plans to target the adult patient population through expanded outreach and new formulations, with a focus on long-term care settings.

Overall, Jazz Pharmaceuticals demonstrated strong financial performance in 2025, with significant growth in key product areas and a strategic focus on rare diseases, despite facing competitive pressures in the sleep segment. The company is poised for continued growth in 2026, with several promising developments in its pipeline.